Skip to main content
Contact Us
Subscribe
E-Edition
65°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Anebulo Pharmaceuticals, Inc. - Common Stock
(NQ:
ANEB
)
1.430
+0.050 (+3.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Anebulo Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
March 13, 2025
Via
Benzinga
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
February 14, 2025
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 24, 2024
Via
Benzinga
Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says
September 18, 2023
H.C.
Via
Benzinga
Anebulo Pharmaceuticals: Q3 Earnings Insights
May 11, 2023
Via
Benzinga
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
December 23, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
November 13, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
September 25, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
July 22, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Lifecore Biomedical Announces Cooperation Agreement with 22NW
July 01, 2024
Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board
From
Lifecore Biomedical, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
June 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
May 31, 2024
Via
Benzinga
ANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024
May 15, 2024
ANEB stock results show that Anebulo Pharmaceuticals beat analyst estimates for earnings per share the third quarter of 2024.
Via
InvestorPlace
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
May 15, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug
February 14, 2024
Substance use disorder-focused biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) reported on Tuesday second quarter financial results for the three months ended Dec. 31, 2023, The...
Via
Benzinga
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
February 13, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
December 21, 2023
Via
Benzinga
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
November 14, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
October 17, 2023
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 17, 2023
Via
Benzinga
Anebulo Pharmaceuticals Announces New CEO
October 06, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
October 06, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
September 20, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
August 30, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023
September 18, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 22, 2023
Via
Benzinga
Anebulo Receives Positive Feedback From FDA On Path To Phase 3 Trial Of Its Drug For Acute Cannabinoid Intoxication
August 21, 2023
Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced positive feedback from the United States Food and Drug Administration following a type B meeting in July.
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
August 21, 2023
Via
Benzinga
Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
August 21, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
